Dr. Sonal Manohar

Areas of Specialisation

Cancer Biology, Cell Signaling

Academic Experience

• Full-time faculty at NMIMS University, Sunandan Divatia School of Science since March 2019 till date
• 3 years Post Doctoral Research at the Department of Chemical Engineering, IIT Bombay, Mumbai, India.
• 6 months as Teaching Assistant, Central FACS facility, IIT Bombay, Mumbai, India.

IndustryExperience

8 years as Research Scientist (Anticancer Drug Discovery) at Piramal Life Sciences Ltd. (previously known as Nicholas Piramal India Ltd.), Mumbai, India.

Education

• 2015-2018: Post Doctoral Fellow, Dept. of Chemical Engineering, IIT Bombay, Mumbai, India.
• 2011-2014: Ph.D. (Applied Biology), Piramal Life Sciences Ltd., University of Mumbai, India.
• 2004-2006: M.Sc. (Life Sciences - Biotechnology), University of Mumbai, India.
• 2001-2004: B.Sc. (Life Sciences), St. Xavier’s College, University of Mumbai, India

Awards and Honors

• Institute Post Doctoral Fellowship 2015-2018: Awarded by Department of Chemical Engineering, IIT Bombay.
• Best Poster award at the 16th TNF Superfamily Meeting held at Biopolis, Singapore in April 2017 for poster titled ‘Topological and functional analysis of comprehensive TNFalpha signaling network’.
• V. B. Kamat award for Best Paper on Post Doctoral Work at the IACR conference held at Amala Cancer Research Institute, Thrissur, Kerala in February, 2017 for oral presentation titled ‘Topological and functional analysis of TNFalpha signaling network reveals specific interactions as potential targets’.
• Special recognition award at Piramal Enterprises Ltd for significant contribution to the hepatotoxicity studies for lead molecules in February 2014.
• Special recognition award at Piramal Life Sciences Ltd for significant contribution to the project titled HIF-1alpha inhibitors in September 2009.
• Rambhau Kulkarni award for the best poster presentation by young scientist at the IACR conference held in IISC, Bangalore in February, 2009 for poster titled, ‘Cyclin dependent kinase inhibitor P276-00 induces apoptosis in multiple myeloma cells by inhibition of Mcl1 and RNA polymerase II-dependent transcription’.
• Departmental Scholarship at the Department of Life Sciences, University of Mumbai in the year 2005-2006.

Selected Publications

• Ramani S, Samant S, Manohar SM* (2022). The story of EGFR: from signaling pathways to a potent anticancer target. Future Medicinal Chemistry 14(17):1267-1288. Impact factor 4.767.
• Manohar SM* (2022). Cyclin-dependent kinases as potential targets for colorectal cancer: past, present and future. Future Medicinal Chemistry 14(14), 1087-1105. Impact factor 4.767.
• Manohar SM*, Joshi KS (2022). Promising anticancer activity of multitarget cyclin dependent kinase inhibitors against human colorectal carcinoma cells. Current Molecular Pharmacology 15(7): 1024-1033. Impact factor 3.855.
• Manohar SM* (2021). A Review of the Botany, Phytochemistry and Pharmacology of Mangrove Lumnitzera racemosa Willd. Pharmacognosy Reviews 2021;15(30):107-116.
• Nair A, Manohar SM* (2021). A flow cytometric journey into cell cycle analysis. Bioanalysis 13(21):1627-1644. Impact factor 2.695.
• Manohar SM*, Shah P, Nair A (2021). Flow Cytometry: Principles, Applications and Recent Advances. Bioanalysis https://doi.org/10.4155/bio-2020-0267. Impact factor 2.695.
• Manohar SM, Shah P, Biswas S, Mukadam A, Joshi M, Viswanathan G (2019). Combining fluorescent cell barcoding and flow cytometry-based phospho-ERK1/2 detection at short time-scales in adherent cells. Cytometry A 95(2): 192-200. Impact factor 4.355. (Issue highlight)
• Aware V, Gaikwad N, Chavan S, Manohar S, Bose J, Khanna S, et al (2015). Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor. European Journal of Medicinal Chemistry 92: 246-256. Impact factor 6.51.
• Godse P, Kumar P, Yewalkar N, Deore V, Lohar M, Mundada R, Padgaonkar A, Manohar S, Joshi A, et al (2013). Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1alpha and STAT-3 pathways. Anticancer Agents in Medicinal Chemistry 13: 1460. Impact factor 2.505.
• Rathos MJ, Khanwalkar H, Joshi K, Manohar SM, Joshi KS (2013). Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells. BMC Cancer 13:29. Impact factor 4.4.
• Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS (2012). Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1alpha and indues G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer and Prostatic Diseases 15:15. Impact factor 5.554.
• Shirsath NP, Manohar SM, Joshi KS (2012). P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. Molecular Cancer 11:77. Impact factor 30.612.
• Rathos MJ, Joshi K, Khanwalkar H, Manohar SM, Joshi KS (2012). Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor P276-00 in pancreatic cancers. Journal of Translational Medicine 10: 161. Impact factor 8.44.
• Patil RC, Manohar SM, Katchi VI, Rao AJ, Moghe A (2012). Ethanolic stem extract of Excoecaria agallocha induces G1 arrest or apoptosis in human lung cancer cells depending on their p53 status. Taiwania: International Journal of Life Sciences 57: 89. Impact factor 0.816.
• Manohar SM, Padgaonkar AA, Jalota-Badhwar A, et al (2011). A novel inhibitor of HIF-1alpha P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. BMC Cancer 11:238. Impact factor 4.4.
• Manohar SM, Rathos MJ, Sonawane V, Rao S, Joshi KS (2011). Cyclin dependent kinase inhibitor P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9 and RNA polymerase II-dependent transcription. Leukemia Research 35: 821. Impact factor 3.715.
• Wagh V, Chile S, Manohar SM, Sharma S, Joshi KS (2011). NPB001-056 specifically inhibits BcrAbl expressing cells by inducing apoptosis and inhibits kinase activity of Bcr-Abl and with T315I mutation. Frontiers in Biosciences E3: 1273. Impact factor 2.717.
• Yewalkar N, Deore V, Padgaonkar A, Manohar SM, Sahu B, Kumar P, et al (2010). Development of novel inhibitors targeting HIF-1alpha towards anticancer drug discovery. Bioorganic and Medicinal Chemistry Letters 20: 6426. Impact factor 2.823.

Patents

• Substituted pyrimidine compounds and uses thereof. Publication number-WO 2013175415 A1. Publication date- November 28, 2013.
• A pharmaceutical combination for the treatment of breast cancer. Publication numberWO 2012069972 A1. Publication date- May 31, 2012.
• Oxadiazole compounds, their preparation and use. Publication number - WO2011104680 A1. Publication date - September 1, 2011.

Book Chapter

• Manohar SM* (2020). Insights into the Molecular Drivers of Prostate Cancer. In: HS Watanabe (Ed.) Horizons in Cancer Research (Vol. 76). Nova Science Publishers, New York, USA (Invited book chapter).

* Corresponding author

Poster/Oral Presentations in Conferences/Meetings

• Manohar S, Shah P, Biswas S, Mukadam A, Joshi M, Viswanathan G. Diagnostic intracellular biomarker detection in adherent cancer cells using high-throughput phospho-flow. Poster presented at the Global Academic Programs Conference 2018, Stockholm, Sweden, May 2018.
• Manohar S, Patil R, Viswanathan G. Topological and functional analysis of comprehensive TNFalpha signaling network. Poster presented at 16th TNF Superfamily Meeting, Singapore, April 2017.
• Manohar S, Patil R, Viswanathan G. Topological and functional analyses of comprehensive TNFalpha signaling network reveals specific interactions as potential targets. Oral presentation at 36th Annual Convention of the IACR, Thrissur, Kerala, February 2017.
• Joshi KS, Manohar S, Jalota-Badhwar A, Sonawane V, et al. Abstract 1822: Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Poster presented at AACR 103rd Annual Meeting 2012- March 2012; Chicago, IL, USA. (Proceedings: Cancer Research: April 15, 2012; 72 (8), Supplement 1.)
• Joshi KS, Padgaonkar A, Rathos M, Wagh V, Manohar S, et al. Abstract 3054: P1446A-05: a new oral cyclin-dependent kinase inhibitor with potent preclinical antitumor activity. Poster presented at AACR 103rd Annual Meeting - March, 2012; Chicago, IL, USA. (Proceedings: Cancer Research: April 15, 2012; 72 (8), Supplement 1.)
• Sharma S, Rathos M, Manohar S, Joshi K, Badhwar A, et al. Abstract P6-15-05: A cyclindependent kinase inhibitor P276 inhibits growth of breast cancer cell lines including basaltype/triple-negative alone and in combination with chemotherapeutic drugs. Poster presented at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium- December 2010; San Antonio, TX, USA. (Proceedings: Cancer Research: December 15, 2010; 70 (24), Supplement 2.)
• Manohar SM, Rathos MJ, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of RNA polymerase-II dependent transcription and down regulation of Mcl-1. Poster presented at 28th Annual Convention of the IACR, February 2009, Bangalore, India.

For complete publications list go to:

https://scholar.google.co.in/citations?user=NI82jhMAAAAJ&hl=en

Citations: 302 h-index: 11 i10-index: 12

Conference/ Workshops Attended

• Global Academic Programs Conference, Karolinska Institute, Stockholm, Sweden, May 2018.
• 16th TNF Superfamily Meeting, Biopolis, Singapore, April 2017.
• Indian Association of Cancer Research (IACR) conference, Amala Cancer Research Institute, Thrissur, Kerala, India, February 2017.
• National meeting for National Network of mathematical and computational biologists (NNMCB), IISER, Pune, India, December 2015.
• Futuristic approach to alternatives: Alternate methods for animal testing, IIT Bombay, Mumbai, India, November 2015.
• The Cytometry Society conference and Indo-US workshop on flow cytometry, NIRRH and ACTREC, Mumbai, India, October 2015.
• Indian Association of Cancer Research (IACR) conference, Indian Institute of Science (IISC), Bangalore, India, February 2009.
• National Conference on Environmental Technology- Biological Perspectives, Issues and Challenges, University of Mumbai, Mumbai, India, February 2006.

Professional Services/Memberships

• Life member of The Cytometry Society India.

Official Email Id

Sonal.Manohar@nmims.edu

Official Phone no.

022-4235-5952.